We employ a rigorously science-driven R&D strategy and have successfully built multiple proprietary technology platforms. These integrated platforms leverage AI and diverse antibody engineering capabilities, including LeadsBody (CD3 T-cell engager platform), X-body (4-1BB engager platform), and TOPiKinectics (ADC Platform).These platforms form the foundation for our continuous innovation across diverse targets, mechanisms of action (MOAs), and therapeutic modalities.

We possess integrated capabilities spanning early discovery, translational medicine, clinical development, CMC (Chemistry, Manufacturing, and Controls), and business development. Leveraging our in-house innovations, we pursue strategic partnerships with industry leaders and venture capital firms. These collaborations accelerate the global clinical advancement and commercialization of our drug candidates, expanding patient access to our transformative therapies.